University of Pittsburgh Scientists Develop Clinical Laboratory Test That Detects Alzheimer’s in Early Stages

Research could lead to new biomarkers that detect Alzheimer’s much earlier than existing tests and help scientists understand why some people with the disease do not develop dementia

Key biomarkers for detecting the progression of Alzheimer’s disease have typically been based on amyloid-beta (Aβ) plaques. But these plaques show up after the disease has well-progressed and aren’t suited to early detection of the disease.

Now, researchers at the University of Pittsburgh School of Medicine (Pitt) have developed a cerebrospinal fluid (CFS) test that detects changes in tau protein prior to the formation of neurofibrillary tangles (NFTs) that proceed Aβ plaques.